Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Nothing but Aristotle revenue and big partnerships
View:
Post by molotov420 on Jun 02, 2021 9:51am

Nothing but Aristotle revenue and big partnerships

will stop this bleeding. Calling out to anyone with some sense....vote against the 2:1
Comment by brad129 on Jun 02, 2021 9:58am
I agree, vote no to split, bring up the Share price to the required amount then come to us. I asked Rebecca to clarify if the 2-1 was approved and enacted prior to deal with HC that they would receive 50% of offered shares, so far no reply. Let the deal close then ask for the 2-1 consolidation as well.  
Comment by Liked2Think on Jun 02, 2021 10:58am
If they do what you brought up as a possibility then yeah thats some serious BS. That would also mean they value the health clinic way too much if you ask me. Although considering they are dead in the water without this additional company when it comes to Aristotle maybe it is worth it.
Comment by Mykndrsn on Jun 02, 2021 12:17pm
Not a chance this won't pass. Common sense, while rare on this board, will prevail. A completely separate issue from the Care acquisition, a contingency if needed that is better to have than not. It may not be necessary but then again it might. Why not have the option? Common sense. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities